Side-by-side comparison of AI visibility scores, market position, and capabilities
Virtual obesity medicine practice with board-certified physicians, dietitians, and coaches; treats obesity as a chronic disease using GLP-1 medications with individualized behavioral plans.
Form Health is a virtual obesity medicine practice that delivers medically supervised weight loss care through a team-based model pairing board-certified obesity medicine physicians with registered dietitians and health coaches, all accessible through a telehealth platform. The practice treats obesity as a complex chronic disease and develops individualized treatment plans that may include anti-obesity medications — including GLP-1 receptor agonists like semaglutide and tirzepatide — alongside nutritional counseling, behavioral health support, and physical activity guidance based on each patient's medical history, comorbidities, and treatment goals. This multidisciplinary approach mirrors the clinical model of a hospital-based obesity medicine program delivered through a scalable virtual format.
Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.
Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.